Julie Philp joins NACDS
ALEXANDRIA, Va. — The National Association of Chain Drug Stores has hired Julie Philp as director of federal affairs to bring additional pharmacy and legislative expertise to the government affairs team. She joins NACDS on April 11.
"Julie is a seasoned advocate with experience in pharmacy and on Capitol Hill, and she will bring a wealth of expertise to NACDS," stated NACDS president and CEO Steve Anderson. "NACDS members will enjoy working with Julie, and we are pleased to welcome her to NACDS’ highly effective team."
Philp, who will report to Paul Kelly, NACDS VP federal government affairs, will play a critical role in conveying to lawmakers the ability of pharmacy services to reduce healthcare costs and improve patient health. She will help advance NACDS’ pro-patient, pro-pharmacy policy advocacy efforts by building and maintaining relationships with members of Congress and their staff, as well as monitoring key healthcare developments on Capitol Hill.
Philp served as director of government relations for the Association of Community Pharmacists and worked with the American Capitol Group on healthcare issues. She also has worked in legislative capacities for Reps. John Campbell, R-Calif.; Michael Burgess, R-Texas; and Ileana Ros-Lehtinen, R-Fla.
Impax says Parkinson’s disease treatment is safe, effective
HAYWARD, Calif. — An investigational drug for Parkinson’s disease was safe and effective, according to results of a late-stage clinical trial scheduled for presentation next week.
Impax Pharmaceuticals, the branded products division of Impax Labs, said it would present data from a phase-3 trial of extended-release IPX066 (carbidopa-levodopa) at the American Academy of Neurology Conference’s annual meeting in Hawaii, which takes place from April 9 through April 16.
The company also said there were no unexpected serious side effects observed in patients.
Watson receives FDA approval for Nulecit
MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic treatment for iron deficiency anemia made by Watson Pharmaceuticals, Watson said Thursday.
The drug maker announced the approval of Nulecit (sodium ferric gluconate complex in sucrose), an injectable and generic version of Sanofi-Aventis’ Ferrlecit.
The drug is used to treat iron deficiency anemia in adults and children ages 6 years and older undergoing chronic hemodialysis and receiving supplemental epoetin therapy.